Jefferies Group LLC - SAGE THERAPEUTICS INC ownership

SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 203 filers reported holding SAGE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.1%.

Quarter-by-quarter ownership
Jefferies Group LLC ownership history of SAGE THERAPEUTICS INC
ValueSharesWeighting
Q3 2022$1,842,478
+66.5%
47,050
+37.4%
0.02%
+66.7%
Q2 2022$1,106,275
+13.3%
34,250
+16.1%
0.01%
+50.0%
Q1 2022$976,450
+33.4%
29,500
+71.5%
0.01%
+50.0%
Q4 2021$731,943
+81.5%
17,206
+89.1%
0.00%
+33.3%
Q3 2021$403,221
-91.7%
9,100
-89.3%
0.00%
-90.3%
Q2 2021$4,844,644
-46.6%
85,278
-29.7%
0.03%
-60.8%
Q1 2021$9,079,305
+22.9%
121,300
+42.0%
0.08%
+38.6%
Q4 2020$7,387,954
+92.7%
85,400
+36.2%
0.06%
+32.6%
Q3 2020$3,833,000
+163.4%
62,700
+79.1%
0.04%
+152.9%
Q2 2020$1,455,000
+388.3%
35,000
+237.7%
0.02%
+466.7%
Q1 2020$298,000
-97.8%
10,365
-94.6%
0.00%
-97.2%
Q4 2019$13,754,000
-32.7%
190,518
+30.8%
0.11%
-32.3%
Q3 2019$20,430,000
-24.9%
145,624
-2.0%
0.16%
-20.2%
Q2 2019$27,213,000
+3.6%
148,629
-10.0%
0.20%
-8.3%
Q1 2019$26,275,000
+264.5%
165,200
+119.5%
0.22%
+266.1%
Q4 2018$7,208,000
+118.1%
75,253
+81.3%
0.06%
+168.2%
Q2 2017$3,305,000
+287.5%
41,500
+245.8%
0.02%
+266.7%
Q1 2017$853,000
-79.9%
12,000
-87.0%
0.01%
-72.7%
Q3 2016$4,247,000
-83.4%
92,226
-89.2%
0.02%
-81.2%
Q2 2016$25,626,000
+11601.4%
850,510
+28250.3%
0.12%
+11600.0%
Q2 2015$219,0003,0000.00%
Other shareholders
SAGE THERAPEUTICS INC shareholders Q3 2022
NameSharesValueWeighting ↓
Integral Health Asset Management, LLC 311,000$10,294,0002.68%
Palo Alto Investors LP 851,719$28,192,0002.18%
Boxer Capital, LLC 1,094,000$36,211,0001.86%
DAFNA Capital Management LLC 180,306$5,968,0001.56%
Deep Track Capital, LP 675,000$22,343,0001.43%
Bellevue Group AG 3,052,404$101,034,0001.17%
Ikarian Capital, LLC 249,907$8,272,0001.09%
Ikarian Capital, LLC 250,000$8,275,0001.09%
Artal Group S.A. 750,000$24,825,0001.04%
SECTOR GAMMA AS 118,476$3,922,0000.85%
View complete list of SAGE THERAPEUTICS INC shareholders